IP Library › Granted Patent US 11,135,153
Granted Patent B2
US 11,135,153 · App. 15/379,866 · Granted Oct 5, 2021

High penetration composition and uses thereof

Inventors: Chongxi Yu (Kensington, MD); Lina Xu (Shanghai, CN)
Assignee: TECHFIELDS PHARMA CO., LTD.
A61K9/0014A61K9/7023A61K31/167A61K31/22A61K31/612A61K47/54A61K47/542C07C231/12C07C233/25
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,135,153
App. No.
15/379,866
Granted
Oct 5, 2021
Kind
B2
Abstract

The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for 4-aminophenol derivatives, which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes. For example, the HPPs can be locally delivered to an action site of a condition with a high concentration due to their ability of penetrating biological barriers and thus obviate the need for a systematic administration. For another example, the HPPs herein can be systematically administer to a biological subject and enter the general circulation with a faster rate.

Claims (16)

1. A compound having the structure:

2. A composition comprising a compound according to Structure 1a:

wherein R 1 and R 2 are each ethyl;

R 3 is H;

A − is Cl − ; and

n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

3. The composition according to claim 2 , further comprising a pharmaceutically acceptable carrier.

4. The composition according to claim 3 , wherein the pharmaceutically acceptable carrier is polar.

5. The composition according to claim 3 , wherein the pharmaceutically acceptable carrier is selected from the group consisiting of alcohol, acetone, ester, buffer, water, isotonic saline and Ringers solution.

6. The composition according to claim 2 , further comprising a pharmaceutically acceptable auxiliary agent selected from the group consisting of pH adjusting agents, buffering agents, and toxicity adjusting agents.

7. The composition according to claim 2 , wherein the concentration of the compound is from 5 weight percent to 20 weight percent.

8. The composition according to claim 2 , wherein the composition is formulated for transdermal administration.

9. The composition according to claim 8 , wherein the composition is formulated as a transdermal patch.

10. The composition according to claim 2 , wherein the composition is formulated as a solution, a spray, a lotion, an ointment, an emulsion or a gel.

11. The composition according to claim 10 , wherein the composition is formulated as a spray.

12. The composition according to claim 11 , wherein the spray is administered orally or nasally.

Assignments (1)
SECURITY INTEREST Recorded Oct 10, 2024
From: TECHFIELDS INC.; TECHFIELDS PHARMA CO., LTD.
To: PREMIER RESEARCH INTERNATIONAL, LLC
Reel/Frame 068869/0278 →
Continuity (14)
Division 12397308 · Mar 3, 2009
Continuation In Part 12351804 · Jan 9, 2009
Continuation In Part PCTIB2006053091 · Sep 3, 2006
Continuation In Part PCTIB2006053741 · Oct 11, 2006
Continuation In Part PCTIB2006053090 · Sep 3, 2006
Continuation In Part PCTIB2006052815 · Aug 15, 2006
Continuation In Part PCTIB2006052732 · Aug 8, 2006
Continuation In Part PCTIB2006052575 · Jul 27, 2006
Continuation In Part PCTIB2006052563 · Jul 26, 2006
Continuation In Part PCTIB2006052549 · Jul 25, 2006
Continuation In Part PCTIB2006052461 · Jul 18, 2006
Continuation In Part PCTIB2006052318 · Jul 9, 2006
Provisional Application 61120052 · Dec 4, 2008
Related Publication 20170151337A1 · Jun 1, 2017